Fusion for Medical Radionuclides
CAN attended the event hosted by UK Atomic Energy Authority (UKAEA) Innovation
Last week, our Scientific Officer, Amin Choudhury and Business Development Manager, Paul Adlem represented Cyclife Aquila Nuclear at the Fusion for Medical Radionuclides Event at Culham Campus, organised by UK Atomic Energy Authority Innovation. The discussions about how fusion technology could revolutionise the production of medical radionuclides were truly enlightening.
The UK currently faces a limited capacity for medical radionuclides, which puts the availability of nuclear medicine treatments at risk. However, the high-energy neutrons produced by deuterium-tritium fusion could open new pathways for creating novel medical radionuclides that are not currently available through existing methods. This development aligns perfectly with our mission to provide comprehensive solutions for processing and supporting nuclear medicine research.
As we continue to support the UK’s journey toward commercialising fusion energy, events like this highlight the vital connection between our fusion expertise and advancements in nuclear medicine.
The potential impact of fusion technology extends far beyond power generation; it will lead to life-saving medical treatments, which is precisely the transformative effect we are passionate about enabling.
Thank you to UKAEA Innovation for hosting such an impactful event. The insights gained will inform our ongoing support for both fusion energy development and innovation in nuclear medicine.
